ACRX Volume Alert - ACRX 6.75 Acelrx Pharmaceuticals $ACRX

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 3:09 PM

ACRX Volume Alert - ACRX 6.75 Acelrx Pharmaceuticals $ACRX Hit a high of 7.04 Currently 11:15 Last price 6.75 +0.72 +11.94% With a day low of 5.93 and a current volume of 1,602,408.

ACRX Acelrx Pharmaceuticals Recent Headline News

AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report
at The Street - Tue Nov 11, 11:00AM CST
Shares of AcelRx Pharmaceuticals (ACRX) surged in late morning trading Tuesday after the company reported third-quarter results after the market close Monday that beat analysts' expectations.
ACRX: 6.92 (+0.89)

Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
ACRX: 6.92 (+0.89), AAWW: 41.63 (-0.12), JOBS: 34.60 (+0.14), AKRX: 35.17 (-0.99), ADVS: 33.16 (-0.29)

Regulus Slumps: RGLS Falls 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:53AM CST
Regulus has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past 24 hours
ACRX: 6.92 (+0.89), AUXL: 32.62 (-0.08), ADHD: 3.65 (-0.02), RGLS: 20.32 (-0.59)

ArQule (ARQL) Catches Eye: Stock Jumps 10.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:30AM CST
ArQule Inc. (ARQL) was a big mover last session, as the company saw its shares rise over 10% on the day.
ACRX: 6.92 (+0.89), AUXL: 32.62 (-0.08), ADHD: 3.65 (-0.02), ARQL: 1.18 (+0.01)

AcelRx revises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:34AM CST

ACRX: 6.92 (+0.89)

AcelRx Pharmaceuticals (ACRX) CEO Richard King on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 10:17PM CST

ACRX: 6.92 (+0.89)

AcelRx Pharmaceuticals beats by $0.09, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:03PM CST

ACRX: 6.92 (+0.89)

AcelRx Pharmaceuticals Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:01PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2014.
ACRX: 6.92 (+0.89)

OTC Daily Alert Stock Watch - AcelRx Pharmaceuticals, Inc (NASDAQ: ACRX)
WorldStockWire - Mon Nov 10, 12:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ACRX: 6.92 (+0.89)

AcelRx Pharmaceuticals Receives International Standards Organization (ISO) 13485:2003 Certification of its Quality Management System
PR Newswire - Mon Nov 10, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has been granted International Standards Organization (ISO) 13485:2003 certification of its quality management system, an internationally recognized quality standard for medical devices issued by the British Standards Institution (BSI).
ACRX: 6.92 (+0.89)

AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events
PR Newswire - Fri Nov 07, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be presenting at the Credit Suisse Annual Healthcare Conference and Jefferies Global Healthcare Conference. Details of the two events are as follows:
ACRX: 6.92 (+0.89)

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
Business Wire - Thu Nov 06, 2:34PM CST
Glancy Binkow & Goldberg LLP reminds investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"

(NASDAQ: ACRX) that those who purchased or otherwise acquired AcelRx's common stock and/or call options, or sold/wrote AcelRx's put options between December 2, 2013 and September 25, 2014, inclusive (the "Class Period"

, have until December 1, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Northern District of California.
ACRX: 6.92 (+0.89)

AcelRx chief bids adieu
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 12:34PM CST

ACRX: 6.92 (+0.89)

AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Monday, November 10, 2014
PR Newswire - Thu Nov 06, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third quarter 2014 financial results after market close on Monday, November 10th, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on November 10, 2014 to discuss the financial results and provide a corporate update.
ACRX: 6.92 (+0.89)

Acelrx Pharmaceuticals Announces Management Change
PR Newswire - Wed Nov 05, 3:00PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the departure of Richard King, the Company's CEO and President. The Board of Directors has initiated a CEO search and Mr. King will remain with the Company as President and Chief Executive Officer while the search is ongoing and during this transition period.
ACRX: 6.92 (+0.89)

Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.92 (+0.89), PTX: 11.17 (+1.26), AKRX: 35.17 (-0.99), RPRX: 9.70 (+0.48), NKTR: 13.83 (+0.04)

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000 Investing in AcelRx Pharmaceuticals, Inc. (ACRX) to Contact the Firm
GlobeNewswire - Fri Oct 31, 4:23PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"

(Nasdaq:ACRX) of the December 1, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against AcelRx and certain executives.
ACRX: 6.92 (+0.89)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in AcelRx Pharmaceuticals, Inc. to Contact Brower Piven Before the December 1, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- ACRX
GlobeNewswire - Wed Oct 29, 12:05PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"

(Nasdaq:ACRX) common stock and/or call options, or sold/wrote AcelRx's put options between December 2, 2013 and September 25, 2014, inclusive (the "Class Period"

. Investors who wish to become proactively involved in the litigation have until December 1, 2014 to seek appointment as lead plaintiff.
ACRX: 6.92 (+0.89)

Can The Uptrend Continue for AcelRx Pharmaceuticals (ACRX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:52AM CDT
Can The Uptrend Continue for AcelRx Pharmaceuticals (ACRX)?
ACRX: 6.92 (+0.89)

Commit To Purchase AcelRx Pharmaceuticals At $5, Earn 15.5% Annualized Using Options
StockOptionsChannel.com - Mon Oct 27, 10:28AM CDT
Investors eyeing a purchase of AcelRx Pharmaceuticals Inc shares, but cautious about paying the going market price of $6.74/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
ACRX: 6.92 (+0.89)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fidelis Care Opens $120K Workforce Grants for Aid

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Sodium Silicate Market To Hit $7.4B by 2031

What's Fueling the Market's Climb? I tell ya, sodium silicate might not be a household name, but it's trekking upwards with a clear purpose. By 2031, this market's expected to touch $7.4 billion from $6 billion in 2026 at a neat 4.4% CAGR. For an old-school trader like me, that's the kind of steady growth that catches my eye. The driving factors? Well, it’s more than...

Right College Fit Crucial for Graduation Rates

Navigating College Choices: More Than Just a Hunch When it comes to picking the right college, a lot of folks think it's like shooting in the dark—it's more than just a blind dart throw at a life map. According to a new report from the College Board, aligning with the right academic institution isn't merely a nice-to-have deal; it fundamentally shifts the odds in favor...

Heritage Wines Meet Non-Alcoholic Trend: New Deal

Wine Industry Shifts Gears Well, here's a twist that might just shake up the wine racks. C. Mondavi & Family, from the historic Charles Krug estate, is aligning with Missing Thorn—a name gaining traction in the non-alcoholic wine scene. It’s a move that not only raises eyebrows but could also expand your wine-tasting options come your next sober night out. So what...

Don Silvestri: NFL Vet's Service Legacy Continues

More Than Just a Debt Guru It's not every day you see a former NFL player shifting gears so smoothly into the corporate world, and then to community service like a missile lock. But that's exactly what Don Silvestri, president of Debt.com, has done. Dragging a hefty reputation as a placekicker for teams like the New York Jets and the Buffalo Bills, he's now making...

Multiplier's Data Signals Global Hiring Evolution

Shaking Up the Global Hiring Playbook You think you know how hiring works globally? Think again. Based on data from a whopping 38,000 cross-border hires, Multiplier's latest Talent Trends has spilled some hot new beans on how companies are rethinking their talent acquisition strategies. This isn’t just some thumb-twiddling speculation either—it’s grounded in real...

Software Updates Costly: UX Not the Biggest Culprit

Breaking Updates Trump UX Changes Here's the real scoop: software updates that break functionality are setting companies back more than those user experience (UX) tweaks that folks gripe about but usually muddle through. According to a recent LITSLINK study, even three figures that supposedly quantify UX losses turn out to be questionable at best. Real-world Disasters:...

Infection Control Market Set for Explosive Growth by 2031

Untangling the Surge in Infection Control Demand Lately, it's like every healthcare joint worldwide is scrambling for better infection control. We're talking about a market poised to jump from a whopping USD 58.5 billion in 2026 to USD 80.2 billion by 2031—a tidy 37% uptick. That change, brewing at a 6.5% CAGR, speaks volumes about where the industry's heading. What's...

Ad Council Expands Board, Taps Meta Exec as Vice Chair

An Unexpected Shuffle at the Ad Council Alright, folks, let's talk shop about the recent shake-up in the nonprofit realm. The Ad Council, which has been around longer than some of the giants controlling today's marketing landscapes, just plumped up its Board of Directors with 23 new heavy-hitters. We're talking about leaders from every nook and cranny of the...

Review Insurance Coverage After Major Life Changes

Why Life Changes Demand an Insurance Review The nitty-gritty of life doesn't sit still—marriages, babies, job changes, and home deals or steals each bring their own clutter to the table. One thing's for sure: when your life shifts, your insurance ought to keep pace. Insurance Agent Nick Hogan drops the dime in the latest HelloNation article, laying it bare why...